Research programme: anticancer monoclonal antibodies - A&G Pharmaceutical

Drug Profile

Research programme: anticancer monoclonal antibodies - A&G Pharmaceutical

Alternative Names: Anti-GP88 monoclonal antibody; Anti-PCDGF monoclonal antibody; Anti-PCDGF-GP88 monoclonal antibody; Anti-PCDGF/GP88 monoclonal antibody; Anti-progranulin monoclonal antibody; CT P4; PC-cell-derived growth factor - A&G Pharmaceutical

Latest Information Update: 16 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator A&G Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors; PC cell-derived growth factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer

Most Recent Events

  • 16 Mar 2016 Preclinical development is ongoing for Breast cancer and Lung cancer in the US (Celltrion pipeline, March 2016)
  • 01 Oct 2015 Preclinical development is ongoing in USA
  • 28 Sep 2010 A&G Pharmaceutical receives SBIR grant from the National Cancer Institute for anticancer monoclonal antibodies development in Breast and Lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top